Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Abstract

This invention relates to novel 8-aza-bicyclo[3.2.1]octane derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

1 - 9 . (canceled) 
     
     
         10 . The chemical compound which is
 exo-3-(Isoquinolin-1-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane;   exo-3-(Fluoren-9-one-2-yloxy)-8-H-8-azabicyclo[3.2.1]octane;   exo-3-(1,2-Benzoisothiazol-3-yloxy)-8-H-8-azabicyclo[3.2.1]octane;   exo-3-(2-Dibenzofuranyloxy)-8-H-8-azabicyclo[3.2.1]octane;   exo-3-(1-Naphthyloxy)-8-H-8-azabicyclo[3.2.1]octane;   exo-3-(2-Naphthyloxy)-8-H-8-azabicyclo[3.2.1]octane;   exo-3-(Quinolin-2-yloxy)-8-H-8-azabicyclo[3.2.1]octane;   exo-3-(Isoquinolin-5-yloxy)-8-H-8-azabicyclo[3.2.1]octane;   exo-3-(Quinolin-6-yloxy)-8-H-8-azabicyclo[3.2.1]octane;   exo-3-(Quinolin-8-yloxy)-8-H-8-azabicyclo[3.2.1]octane;   exo-3-(Isoquinolin-1-yloxy)-8-H-8-azabicyclo[3.2.1]octane;   
       or a pharmaceutically acceptable salt thereof. 
     
     
         11 . A pharmaceutical composition, comprising a therapeutically effective amount of a compound of  claim 10 , or any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent. 
     
     
         12 - 14 . (canceled)